WELCOME TO
NOSEVAC
The international partnership to advance the development of new vaccines against upper respiratory tract pathogens
The NOSEVAC project aims at developing and evaluating innovative nasal vaccine platforms as a novel approach to prevent the earliest stage of infection, thereby inhibiting upper respiratory tract (URT) colonisation, transmission and disease.
Under the European Vaccine Initiative (EVI) coordination, the NOSEVAC project builds on a unique consortium of 13 complementary teams from the EU, UK and Switzerland.
AT A GLANCE
TIMELINE
1 May 2023
to 30 April 2028
COORDINATOR
European Vaccine Initiative (EVI)
FUNDER
European Union,
UKRI and SERI
FUNDING
€11.6 Million
The project focuses on four major respiratory pathogens: Streptococcus pneumoniae or pneumococcus, Bordetella, influenza virus, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for diseases with major impact on public health: community-acquired pneumonia (CAP), whooping cough, influenza and Coronavirus Disease 2019 (COVID-19), respectively.
NOSEVAC aims to combine innovative formulations and manufacturing processes to deliver and evaluate bivalent RNA- and protein-based nasal vaccines against bacterial and viral infection, respectively.